• MK-1775: Wee1 Kinase Inhibitor Research Guide

  2026-09-18

  MK-1775 is a selective Wee1 kinase inhibitor that blocks inhibitory CDC2 phosphorylation and disrupts the G2 DNA damage checkpoint. Its strongest research rationale is combination testing with DNA-damaging agents in p53-deficient tumor models, while separate measurements of growth arrest and cell death are needed for accurate interpretation.

• Toremifene in Prostate Cancer: Linking ER and Ca2+

  2026-09-18

  Toremifene provides a receptor-level lens for prostate cancer research, while emerging evidence on the TSPAN18–STIM1–Ca2+ axis suggests a practical path from hormone signaling to metastatic mechanism.

• T0070907: A Strategic Probe of PPARγ Biology

  2026-09-17

  T0070907 is more than a potent PPARγ antagonist: it is a mechanistically informative tool for separating receptor-dependent transcription from context-specific cellular effects. This article connects PPARγ/RXRα biology, adipogenesis inhibition, cancer cell-cycle phenotypes, and the RXRα/PPARγ/NEDD4 axis described in atherosclerosis research.

• Thymoquinone: Designing Better Cardiotoxicity Assays

  2026-09-17

  Thymoquinone offers a useful framework for studying doxorubicin-associated cardiac injury beyond generic antioxidant testing. This article translates mouse findings on Nrf2/HO-1 signaling, ferroptosis, and mitochondrial preservation into a practical, multi-readout assay strategy.

• Thioredoxin System Drives CHK1 Inhibitor Sensitivity

  2026-09-16

  A 2024 Nature Communications study identifies thioredoxin 1 as a determinant of CHK1 inhibitor sensitivity in non-small cell lung cancer. Its data connect thioredoxin-dependent redox recycling of RRM1, ribonucleotide reductase activity, and deoxynucleotide availability, providing a mechanistic rationale for combining CHK1 and thioredoxin reductase inhibition.

• NAT1–ENO1–Lactate Signaling in Colorectal Cancer

  2026-09-16

  A 2026 MedComm study identifies a NAT1–ENO1–lactate pathway that links tumor glycolysis to PD-L1 stabilization and immune escape in colorectal cancer. Its combination of multi-omics, biochemical experiments, patient datasets, and mouse models provides a mechanistic framework for studying how lactate metabolism may influence checkpoint-blockade responses.

• T0070907: Practical PPARγ Assay Design

  2026-09-15

  A scenario-based guide to using T0070907 (SKU A4301) as a defined PPARγ antagonist in adipogenesis, viability, and cancer cell-cycle studies. It connects biochemical potency with practical stock preparation, controls, interpretation, and vendor-selection criteria.

• GKT137831: Nox1/Nox4 Redox Research Workflows

  2026-09-15

  GKT137831 enables controlled interrogation of Nox1/Nox4-driven oxidative signaling in pulmonary, vascular, metabolic, and fibrotic models. This workflow-focused guide connects ROS suppression with emerging ferroptosis and plasma-membrane biology while clearly separating established applications from exploratory assay extensions.

• FCCP for Reliable Mitochondrial Assays

  2026-09-14

  This scenario-based guide explains how FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone), SKU B5004, can improve the design and interpretation of mitochondrial, viability, and HIF-related assays. It connects practical dosing, solvent, storage, vendor-selection, and immunometabolic considerations with product data and peer-reviewed evidence.

• Baicalein Workflows for Redox-Aware Cancer Assays

  2026-09-14

  Baicalein provides a practical 12-LOX perturbation tool for connecting arachidonic acid metabolism with cancer proliferation, apoptosis, and inflammatory signaling. This workflow pairs pathway engagement with redox, viability, and selectivity measurements inspired by recent neurotoxicity research, helping distinguish useful biology from solvent, precipitation, or nonspecific cytotoxicity.

• Lovastatin: HMG-CoA Reductase Inhibitor Guide

  2026-09-13

  Lovastatin is a cell-active HMG-CoA reductase inhibitor that suppresses mevalonate production and downstream cholesterol and isoprenoid synthesis. Product-reported benchmarks support research applications in cholesterol metabolism, cancer research, apoptosis, fibroblast biology, mesangial proliferation, and macrophage efferocytosis, but assay-specific potency should not be generalized across models.

• Apicidin Workflows for HDAC and Cell Assays

  2026-09-12

  Apicidin is a mechanistically useful histone deacetylase inhibitor for connecting HDAC3/HDAC6 activity with chromatin, cytoskeletal, cancer, parasite, and oocyte phenotypes. This workflow-focused guide covers solvent handling, dose design, orthogonal readouts, and troubleshooting for reproducible bench studies.

• Zoledronic Acid: Cancer Assay Workflows

  2026-09-11

  Build reproducible Zoledronic Acid workflows for cancer cell apoptosis, breast cancer models, multiple myeloma treatment research, and osteolytic bone disease prevention. This guide emphasizes formulation control, orthogonal readouts, and cautious translation of mechanistic methods from a recent immune-metabolism study.

• AO/PI Staining Solution for Mechanistic Cell Assays

  2026-09-11

  Discover how AO/PI Staining Solution improves fluorescence-based cell counting in inflammation and apoptosis research. This guide connects membrane-integrity measurements with the mechanistic findings of a diabetic nephropathy study while defining practical assay decisions and limitations.

• Baicalein: 12-LOX Research Guide

  2026-09-10

  Baicalein, also called 5,6,7-trihydroxy-2-phenylchromen-4-one, is a flavonoid research compound used to study 12-lipoxygenase, arachidonic acid metabolism, apoptosis, inflammation, and cancer-cell biology. Product data describe a 270.24 g/mol solid with limited water solubility and high solubility in DMSO, while current neurotoxicity evidence supports formononetin rather than baicalein.

8713 records 1/581 page Next 12345 下5页 Last page